Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for ERIS
Revenue projections for ERIS

Revenues for ERIS are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 0.885000
forwardPE 30.928219
debtToEquity 75.737000
earningsGrowth 0.315000
revenueGrowth 0.284000
grossMargins 0.745350
operatingMargins 0.249740
trailingEps 28.390000
forwardEps 41.650000

Positive earnings and revenue growth for Eris Lifesciences Limited point to expected business expansion. The company is projected to continue growing its operations, as increasing profits and sales highlight a strong trajectory for further growth in the future.
Positive gross and operating margins for ERIS highlight the company's profitability. These metrics reflect ERIS's efficiency in controlling costs while generating strong revenue from its core operations, signaling robust financial health.
ERIS's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for ERIS's financial growth.

Price projections:

Price projections for ERIS
Price projections for ERIS

Price projections for Eris Lifesciences Limited have been revised upward over time, signaling increasing optimism about the company's future. This steady increase reflects a positive outlook for Eris Lifesciences Limited's growth and market performance.

Recommendation changes over time:

Recommendations trend for ERIS
Recommendations trend for ERIS


Analysts' buy bias toward Eris Lifesciences Limited suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, Eris Lifesciences Limited is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.